专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US08318856B2 Nucleic acid delivery system comprising conjugates of PEI and hyaluronic acid 有权
标题翻译：包含PEI和透明质酸的缀合物的核酸递送系统
公开(公告)号：US08318856B2
公开(公告)日：2012-11-27
申请号：US12733061
申请日：2008-04-04
申请人： Yu-Kyoung Oh , Hyun-Gu Kang , Ji-Seok Kim , Jiang Ge , Ki-Su Kim , Ki-Tae Park , Su-Eun Han , Ga-Yong Shim , Ii-Hwan Cho , Sei-Kwang Hahn
发明人： Yu-Kyoung Oh , Hyun-Gu Kang , Ji-Seok Kim , Jiang Ge , Ki-Su Kim , Ki-Tae Park , Su-Eun Han , Ga-Yong Shim , Ii-Hwan Cho , Sei-Kwang Hahn
IPC分类号： C08B37/00 , C08G63/48 , C08G63/91 , A61K48/00
CPC分类号： A61K47/61 , A61K47/59
摘要： The present invention relates to a delivery system for nucleic acid using a cationic polymer conjugate, and more specifically relates to a delivery system for nucleic acid comprising a cationic polymer conjugate prepared by conjugating hyaluronic acid or its derivative and polyethyleneimine, and a composition of delivering a nucleic acid into mammalian cell comprising a complex of the nucleic acid and a cationic polymer conjugate with electrostatic binding.
摘要翻译：本发明涉及使用阳离子聚合物缀合物的核酸递送系统，并且更具体地涉及用于核酸的递送系统，其包含通过将透明质酸或其衍生物和聚乙烯亚胺缀合而制备的阳离子聚合物缀合物，以及递送核酸进入哺乳动物细胞，其包含核酸和具有静电结合的阳离子聚合物缀合物的复合物。

2. 发明申请

US20100144035A1 Delivery system for nucleic acids using cationic polymer conjugates 有权
标题翻译：使用阳离子聚合物共轭物的核酸递送系统
公开(公告)号：US20100144035A1
公开(公告)日：2010-06-10
申请号：US12733061
申请日：2008-04-04
申请人： Yu-Kyoung Oh , Hyun-Gu Kang , Ji-Seok Kim , Jiang Ge , Ki-Su Kim , Ki-Tae Park , Su-Eun Han , Ga-Yong Shim , II-Hwan Cho , Sei-Kwang Hahn
发明人： Yu-Kyoung Oh , Hyun-Gu Kang , Ji-Seok Kim , Jiang Ge , Ki-Su Kim , Ki-Tae Park , Su-Eun Han , Ga-Yong Shim , II-Hwan Cho , Sei-Kwang Hahn
IPC分类号： C12N5/00 , C08G63/91
CPC分类号： A61K47/61 , A61K47/59
摘要： The present invention relates to a delivery system for nucleic acid using a cationic polymer conjugate, and more specifically relates to a delivery system for nucleic acid comprising a cationic polymer conjugate prepared by conjugating hyaluronic acid or its derivative and polyethyleneimine, and a composition of delivering a nucleic acid into mammalian cell comprising a complex of the nucleic acid and a cationic polymer conjugate with electrostatic binding.
摘要翻译：本发明涉及使用阳离子聚合物缀合物的核酸递送系统，并且更具体地涉及用于核酸的递送系统，其包含通过将透明质酸或其衍生物和聚乙烯亚胺缀合而制备的阳离子聚合物缀合物，以及递送核酸进入哺乳动物细胞，其包含核酸和具有静电结合的阳离子聚合物缀合物的复合物。

3. 发明申请

US20120021044A1 Novel Cationic Lipid, A Preparation Method of the Same and A Delivery System Comprising the Same 审中-公开
标题翻译：新型阳离子脂质，其制备方法及其输送系统
公开(公告)号：US20120021044A1
公开(公告)日：2012-01-26
申请号：US12672910
申请日：2008-08-20
申请人： Yu-Kyoung Oh , Min-Sung Suh , Hye-Jeong Shin , Ga Yong Shim
发明人： Yu-Kyoung Oh , Min-Sung Suh , Hye-Jeong Shin , Ga Yong Shim
IPC分类号： A61K31/7088 , A61K9/127 , A61K47/44 , A61P35/00 , A61P19/02 , A61P9/00 , A61P5/00 , C07C237/06 , C07H21/00 , B82Y5/00
CPC分类号： C07C237/06 , C12N15/88
摘要： The present invention provides a novel cationic lipid, a preparation method of the same and a delivery system comprising the same. The cationic lipid of the present invention is used for the preparation of delivery systems of nucleic acids or physiologically active anionic proteins. The cationic lipid of the present invention can be conveniently prepared and purified by a simple process and is therefore economically highly advantageous for industrial-scale production thereof. Further, a nucleic acid or protein delivery system comprising the cationic lipid of the present invention not only significantly improves the intracellular delivery efficiency of desired nucleic acid drugs (such as DNAs, RNAs, siRNAs, antisense oligonucleotides, and nucleic acid aptamers) or anionic proteins having physiological activity, but also is usefully used to augment therapeutic efficacy of nucleic acid or protein drugs due to attenuated cytotoxicity of the delivery system.
摘要翻译：本发明提供了一种新型的阳离子脂质，其制备方法和包含其的递送系统。本发明的阳离子脂质用于制备核酸或生理活性阴离子蛋白的递送系统。本发明的阳离子脂质可以通过简单的方法方便地制备和纯化，因此在其工业规模生产方面经济上是非常有利的。此外，包含本发明的阳离子脂质的核酸或蛋白质递送系统不仅显着地改善了期望的核酸药物（例如DNA，RNA，siRNA，反义寡核苷酸和核酸适配体）或阴离子蛋白质的细胞内递送效率具有生理活性，但也有用地用于增加核酸或蛋白质药物由于递送系统的减毒细胞毒性的疗效。

4. 发明授权

US07745419B2 Pharmaceutical composition for treating cancer 有权
标题翻译：用于治疗癌症的药物组合物
公开(公告)号：US07745419B2
公开(公告)日：2010-06-29
申请号：US12234271
申请日：2008-09-19
申请人： Yu-Kyoung Oh , Ga Yong Shim , Sang-Hee Kim
发明人： Yu-Kyoung Oh , Ga Yong Shim , Sang-Hee Kim
IPC分类号： C07H21/02 , C07H21/04 , A61K31/70
CPC分类号： A61K31/7105 , A61K9/1272 , C12N15/113 , C12N2310/14
摘要： The present invention provides a small interfering RNA (siRNA) that is capable of inhibiting intracellular expression of Wnt1 through complementary binding to a Wnt1 transcript (mRNA transcript) base sequence and a pharmaceutical composition for treating cancer comprising the same. siRNA of the present invention which is complementary to a base sequence of a Wnt1 transcript (mRNA) provides apoptotic cancer cell death due to inhibition of expression of Wnt1 commonly expressed in cancer cells, by RNA-mediated interference (RNAi). Therefore, the composition of the present invention comprising the same can be used as an excellent anticancer drug.
摘要翻译：本发明提供能够通过与Wnt1转录物（mRNA转录物）碱基序列的互补结合和用于治疗癌症的药物组合物来抑制Wnt1的细胞内表达的小干扰RNA（siRNA）。通过RNA介导的干扰（RNAi），通过抑制通常在癌细胞中表达的Wnt1的表达，本发明的与Wnt1转录物（mRNA）的碱基序列互补的siRNA提供了凋亡性癌细胞死亡。因此，包含该组合物的本发明的组合物可以用作优异的抗癌药物。

5. 发明申请

US20100203112A1 COMPOSITION OF CATIONIC PHOSPHOLIPID NANOPARTICLES FOR EFFECTIVE DELIVERY OF NUCLEIC ACIDS 审中-公开
标题翻译：用于有效递送核酸的阳离子磷脂纳米颗粒的组合物
公开(公告)号：US20100203112A1
公开(公告)日：2010-08-12
申请号：US12593773
申请日：2008-03-28
申请人： Yu-Kyoung Oh , Hye-Jeong Shin , Min-Sung Suh , Ga Yong Shim
发明人： Yu-Kyoung Oh , Hye-Jeong Shin , Min-Sung Suh , Ga Yong Shim
IPC分类号： A61K9/127 , A61P35/04 , A61K31/7088 , C12N5/02
CPC分类号： A61K9/1272 , A61K47/543 , A61K47/6911
摘要： The present invention provides a cationic phospholipid liposome composition comprising 1,2-dioleoyl-sn-glycero-S-ethylphosphocholine (EDOPC), 3β-[N—(N′,N′-dimethylaminoethane)-carbamoyl] cholesterol (DC-cholesterol) and 1,2-diphytanoyl-sn-glycero-3-phosphoethanolamine (DPhPE), a liposome-nucleic acid complex which is capable of forming a complex therewith, and a pharmaceutical composition comprising the same. The cationic phospholipid liposome of the present invention is highly effective for intracellular delivery of nucleic acids and reduction of cytotoxicity, as compared to conventional liposome products. Therefore, the present invention can be useful for gene therapy via intracellular delivery of a desired material to target cells.
摘要翻译：本发明提供一种阳离子磷脂脂质体组合物，其包含1,2-二油酰-sn-甘油基-S-乙基磷酸胆碱（EDOPC），3β-[N-（N'，N'-二甲基氨基乙烷） - 氨基甲酰]胆固醇（DC-胆固醇）和1,2-二草酰基-sn-甘油基-3-磷酸乙醇胺（DPhPE），其能够与其形成复合物的脂质体 - 核酸复合物和包含其的药物组合物。与常规脂质体产品相比，本发明的阳离子磷脂脂质体对核酸的细胞内递送和细胞毒性的降低是非常有效的。因此，本发明可用于通过细胞内递送所需材料到靶细胞的基因治疗。

6. 发明授权

US08431543B2 Chitosan based polymer conjugate and a method for producing the same 有权
标题翻译：壳聚糖基聚合物共轭物及其制备方法
公开(公告)号：US08431543B2
公开(公告)日：2013-04-30
申请号：US12522215
申请日：2008-01-07
申请人： Myung-Ok Park , Yu-Kyoung Oh , Sang Myoung Noh , Sung Sik Bang , Myung Suk Kim
发明人： Myung-Ok Park , Yu-Kyoung Oh , Sang Myoung Noh , Sung Sik Bang , Myung Suk Kim
IPC分类号： A61K48/00 , A61P43/00 , C12Q1/68
CPC分类号： C12N15/87 , A61K9/5161 , A61K47/36
摘要： The present invention relates to a conjugate of chitosan and polyamine polymer that is useful for transferring a desired gene medicine into cells, and a method for preparing the same. In particular, the present invention relates to a double conjugate that is prepared by 1 in king poly-L-arginine to low molecular weight chitosan or triple conjugate that is prepared by additionally linking polyethylene glycol (PEG) to the double conjugate, and a method for preparing the same. The chitosan based cationic polymer conjugate of the present invention forms a complex with negatively charged gene medicine such as plasmid DNA and small interfering RNA to efficiently transfer the desired gene medicine into cells with low cytotoxicity. Accordingly, the conjugate can be used as an effective delivery system for in vivo administration of gene medicine.
摘要翻译：本发明涉及可用于将期望的基因药物转移到细胞中的壳聚糖和多胺聚合物的缀合物及其制备方法。特别地，本发明涉及通过将聚乙二醇（PEG）与双重缀合物另外连接而制备的由聚异丁酰胺聚合物1中的1与低分子量壳聚糖或三重缀合物制备的双重缀合物，为准备相同。本发明的基于壳聚糖的阳离子聚合物缀合物与带负电荷的基因药物如质粒DNA和小干扰RNA形成复合物，以有效地将期望的基因药物转移到具有低细胞毒性的细胞中。因此，缀合物可以用作体内施用基因药物的有效递送系统。

7. 发明申请

US20100285056A1 Baculovirus-Based Vaccines 审中-公开
标题翻译：基于杆状病毒的疫苗
公开(公告)号：US20100285056A1
公开(公告)日：2010-11-11
申请号：US12812053
申请日：2009-01-09
申请人： Young-Bong Kim , Hee Jung Lee , Nuri Park , Yu-Kyoung Oh
发明人： Young-Bong Kim , Hee Jung Lee , Nuri Park , Yu-Kyoung Oh
IPC分类号： A61K39/12 , C12N7/01 , C07H21/04 , A61P37/04 , A61P31/20 , A61P35/00
CPC分类号： A61K39/12 , A61K2039/5256 , C12N7/00 , C12N15/86 , C12N2710/14143 , C12N2710/14145 , C12N2710/14171 , C12N2710/20034 , C12N2740/10022 , C12N2800/22 , C12N2810/6054 , C12N2830/60 , C12N2830/85
摘要： The present invention relates to a recombinant baculovirus comprising: (a) a nucleotide sequence encoding a foreign virus envelope protein; (b) a first promoter operatively linked to the envelope-encoding nucleotide sequence; (c) a nucleotide sequence encoding an antigen protein; and (d) a second promoter operatively linked to the antigen-encoding nucleotide sequence; and a vaccine composition using the same. The recombinant baculovirus of the present invention has an excellent efficacy on both humoral and cellular immune responses against a specific antigen (e.g., HPV L1), enabling to function as a more efficient DNA vaccine.
摘要翻译：本发明涉及重组杆状病毒，其包含：（a）编码外来病毒包膜蛋白的核苷酸序列; （b）可操作地连接到包膜编码核苷酸序列的第一启动子; （c）编码抗原蛋白的核苷酸序列; 和（d）与抗原编码核苷酸序列可操作地连接的第二启动子; 和使用其的疫苗组合物。本发明的重组杆状病毒对针对特异性抗原（例如HPV L1）的体液和细胞免疫应答具有优异的功效，能够起到更有效的DNA疫苗的作用。

8. 发明授权

US08846630B2 Pharmaceutical composition for treating cancer 有权
标题翻译：用于治疗癌症的药物组合物
公开(公告)号：US08846630B2
公开(公告)日：2014-09-30
申请号：US13512583
申请日：2010-11-01
申请人： Misun Won , Kyung-Sook Chung , Young Joo Kim , Hye Kyung Hong , Young Il Yeom , Chae Ok Yun , Yu-Kyoung Oh , Kyung Bin Song , Hee Gu Lee , Young Ho Kim , Moon Hee Kim , Kyeong-Eun Jung , Seok Hoon Song
发明人： Misun Won , Kyung-Sook Chung , Young Joo Kim , Hye Kyung Hong , Young Il Yeom , Chae Ok Yun , Yu-Kyoung Oh , Kyung Bin Song , Hee Gu Lee , Eun Young Song , Young Ho Kim , Moon Hee Kim , Kyeong-Eun Jung
IPC分类号： C12N15/11 , C07H21/04 , A61K31/711 , A61K31/713 , A61K31/7105
CPC分类号： C12N15/113 , A61K31/7105 , A61K31/711 , A61K31/713 , C12N2310/531
摘要： The present invention provides a pharmaceutical composition for treating cancer, comprising at least one selected from deoxyribonucleic acids (DNA) for encoding small interfering RNA (siRNA) which complementarily binds to the base sequence of the transcript (mRNA transcript) of the FLJ25416 gene, represented by sequence number 3, sequence number 5, and sequence number 7 to inhibit the intracellular expression of the FLJ25416 gene, antisense RNA which inhibits expression of the FLJ25416 gene, and short hairpin RNA (shRNA) which inhibits expression of the FLJ25416 gene. As the siRNA, which is complementary to the base sequence of the transcript (mRNA transcript) of the FLJ25416 gene, the antisense RNA, and the shRNA, according to the present invention, inhibit expression of the FLJ25416 gene which is known to be expressed in cancer cells, and thus kill cancer cells, the composition of the present invention can be used as a novel anti-cancer agent.
摘要翻译：本发明提供了一种用于治疗癌症的药物组合物，其包含选自用于编码与FLJ25416基因的转录物（mRNA转录物）的碱基序列互补结合的小干扰RNA（siRNA）的脱氧核糖核酸（DNA）中的至少一种，代表通过序列号3，序列号5和序列号7来抑制FLJ25416基因的细胞内表达，抑制FLJ25416基因表达的反义RNA和抑制FLJ25416基因表达的短发夹RNA（shRNA）。作为与根据本发明的FLJ25416基因，反义RNA和shRNA的转录物（mRNA转录物）的碱基序列互补的siRNA抑制FLJ25416基因的表达，已知其表达于癌细胞，因此杀死癌细胞，本发明的组合物可以用作新的抗癌剂。

9. 发明申请

US20130028957A1 PHARMACEUTICAL COMPOSITION FOR TREATING CANCER 有权
标题翻译：用于治疗癌症的药物组合物
公开(公告)号：US20130028957A1
公开(公告)日：2013-01-31
申请号：US13512583
申请日：2010-11-01
申请人： Misun Won , Kyung-Sook Chung , Young Joo Kim , Hye Kyung Hong , Young Il Yeom , Chae Ok Yun , Yu-Kyoung Oh , Kyung Bin Song , Hee Gu Lee , Young Ho Kim , Moon Hee Kim , Kyeong-Eun Jung , Seok Hoon Song
发明人： Misun Won , Kyung-Sook Chung , Young Joo Kim , Hye Kyung Hong , Young Il Yeom , Chae Ok Yun , Yu-Kyoung Oh , Kyung Bin Song , Hee Gu Lee , Eun Young Song , Young Ho Kim , Moon Hee Kim , Kyeong-Eun Jung
IPC分类号： A61K31/7105 , C07H21/04 , A61P35/00 , A61K31/711 , A61K9/127 , C07H21/02 , A61K31/713
CPC分类号： C12N15/113 , A61K31/7105 , A61K31/711 , A61K31/713 , C12N2310/531
摘要： The present invention provides a pharmaceutical composition for treating cancer, comprising at least one selected from deoxyribonucleic acids (DNA) for encoding small interfering RNA (siRNA) which complementarily binds to the base sequence of the transcript (mRNA transcript) of the FLJ25416 gene, represented by sequence number 3, sequence number 5, and sequence number 7 to inhibit the intracellular expression of the FLJ25416 gene, antisense RNA which inhibits expression of the FLJ25416 gene, and short hairpin RNA (shRNA) which inhibits expression of the FLJ25416 gene. As the siRNA, which is complementary to the base sequence of the transcript (mRNA transcript) of the FLJ25416 gene, the antisense RNA, and the shRNA, according to the present invention, inhibit expression of the FLJ25416 gene which is known to be expressed in cancer cells, and thus kill cancer cells, the composition of the present invention can be used as a novel anti-cancer agent.
摘要翻译：本发明提供了一种用于治疗癌症的药物组合物，其包含选自用于编码与FLJ25416基因的转录物（mRNA转录物）的碱基序列互补结合的小干扰RNA（siRNA）的脱氧核糖核酸（DNA）中的至少一种，代表通过序列号3，序列号5和序列号7来抑制FLJ25416基因的细胞内表达，抑制FLJ25416基因表达的反义RNA和抑制FLJ25416基因表达的短发夹RNA（shRNA）。作为与根据本发明的FLJ25416基因，反义RNA和shRNA的转录物（mRNA转录物）的碱基序列互补的siRNA抑制FLJ25416基因的表达，已知其表达于癌细胞，因此杀死癌细胞，本发明的组合物可用作新的抗癌剂。

10. 发明申请

US20110160282A1 NUCLEIC-ACID PHARMACEUTICAL COMPOSITION FOR CANCER THERAPY 审中-公开
标题翻译：用于癌症治疗的核酸药物组合物
公开(公告)号：US20110160282A1
公开(公告)日：2011-06-30
申请号：US12735809
申请日：2009-02-18
申请人： Yu-Kyoung Oh , Gayong Shim , Sang-Hee Kim
发明人： Yu-Kyoung Oh , Gayong Shim , Sang-Hee Kim
IPC分类号： A61K31/713 , C07H21/00 , A61P35/00
CPC分类号： C12N15/1135 , C12N2310/14 , C12N2310/315
摘要： The present invention provides at least one siRNA (small interfering RNA) which inhibits the expression of Mcl-1 within the cell, and which is selected from siRNA having SEQ. ID. NO. 1 sense sequence and SEQ. ID. NO. 2 antisense sequence, siRNA having SEQ. ID. NO. 3 sense sequence and SEQ. ID. NO. 4 antisense sequence, and siRNA having SEQ. ID. NO. 5 sense sequence and SEQ. ID. NO. 6 antisense sequence. The invention also provides a nucleic-acid pharmaceutical composition for cancer therapy comprising the same. The siRNA of the present invention kills cancer cells by inhibiting the expression of Mcl-1 which is commonly expressed in cancer cells by means of RNA-mediated interference (RNAi), and the composition of the present invention can be used as an outstanding anti-cancer preparation.
摘要翻译：本发明提供了抑制细胞内Mcl-1表达的至少一种siRNA（小干扰RNA），其选自具有SEQ ID NO：1的siRNA。 ID。没有。 1有义序列和SEQ。 ID。没有。 2反义序列，具有SEQ ID NO： ID。没有。 3有义序列和SEQ。 ID。没有。 4反义序列，和具有SEQ ID NO： ID。没有。 5有义序列和SEQ。 ID。没有。 6反义序列。本发明还提供了包含其的癌症治疗用核酸药物组合物。本发明的siRNA通过抑制通过RNA介导的干扰（RNAi）在癌细胞中通常表达的Mcl-1的表达来杀死癌细胞，本发明的组合物可以用作突出的抗 - 癌症准备。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式